Prior biologic class shapes anti-TNF success in IBD — but not equally for all patients

Loading Curie Briefs...

Getting the latest healthcare news for you

Prior biologic class shapes anti-TNF success in IBD — but not equally for all patients | Curie Briefs

Prior biologic class shapes anti-TNF success in IBD — but not equally for all patients

5 days ago•Medscape

Summary

When it comes to treating inflammatory bowel disease, the order of biologics matters. A new real-world study found that ulcerative colitis patients who switched to anti-TNF therapy after a biologic with a different mechanism of action were nearly twice as likely to discontinue treatment. Crohn's disease patients, however, didn't show the same pattern.

Prior biologic class shapes anti-TNF success in IBD — but not equally for all patients

Sequencing biologics in inflammatory bowel disease (IBD) is more nuanced than just counting prior treatment failures. A new real-world study from Spain's ENEIDA registry found that the type of biologic used before anti-TNF therapy significantly influences how well patients respond — but the impact differs depending on whether they have ulcerative colitis (UC) or Crohn's disease (CD).

The study tracked 183 IBD patients (66 with CD, 117 with UC) who received a non-anti-TNF biologic (like vedolizumab or ustekinumab) before switching to anti-TNF therapy, comparing them to matched patients on first-line anti-TNF or those who had previously used another anti-TNF.

Key Takeaways:

UC patients switching to anti-TNF after a different-mechanism biologic were 89% more likely to discontinue treatment (adjusted HR 1.89)
Clinical remission rates in UC were significantly lower at both 16 weeks (20% vs. 34% vs. 39%) and 52 weeks (18% vs. 34% vs. 42%)
No significant difference in durability or remission was seen in CD patients across the three groups
Adverse event-related discontinuation rates were similar across all cohorts

Why it matters: This is the first real-world evidence showing that prior biologic mechanism of action — not just the number of prior therapies — can critically shape subsequent treatment outcomes in IBD, particularly for UC patients. Clinicians may need to factor in the full biologic history when planning next-line therapy.

Curie Brief

Loading Curie Briefs...

Curie Brief

Curie Brief

Prior biologic class shapes anti-TNF success in IBD — but not equally for all patients

Summary

Prior biologic class shapes anti-TNF success in IBD — but not equally for all patients

Related stories

Fiber and your gut: Why what you eat shapes your microbiome and your health

Gut bug, brain risk: H. pylori infection linked to higher odds of Parkinson's disease

Risankizumab outperforms ustekinumab as a steroid-sparing therapy for Crohn's disease